Neurology Solutions for more diagnostic confidence
Imaging and Lab Tests support Alzheimer’s disease Evaluation
At the moment, there are no stand-alone tests for a definitive diagnosis of Alzheimer’s disease (AD) other than histopathological confirmation at autopsy. Complete work up of AD includes a thorough medical history, mental status testing, physical and neurological exam, brain imaging and laboratory tests.
Moving towards earlier detection
In the future, new imaging technologies and disease biomarkers may be helpful to take the clinical evaluation of AD forward from simply ruling out the disease to supporting the identification of patients who have the strong likelihood of developing AD, by identifying characteristic patterns of functional and structural cerebral alterations. The actual guidelines for the Mild Cognitive Impairment (MCI) stage are largely for research, but they may be applied in specialized clinical settings. They supplement standard clinical tests to help determine possible causes of MCI symptoms.1
Currently, imaging is being used in research to help establish correlations between pathophysiologic manifestations, clinical status and their relation to other biomarkers, and their prognosis as well as therapeutic trials. Going forward, imaging could be valuable to identify which MCI patients might progress to a clinical diagnosis of AD and support the identification of proper disease modifying therapies.2
Combining diagnostic imaging and laboratory capabilities, Siemens is your partner in the evaluation of AD and in pushing diagnostic boundaries going forward.
1Clifford R. J.et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3) 257-262
2Clifford R. J. Alzheimer disease: New Concepts on Its Neurobiology and the Clinical Role Imaging Will Play. Radiology 2012;263 (2): 344-361